China waives tariffs on some U.S. goods, but denies Trump's claim that talks are underway
By Andrew Silver, Trixie Yap and Gram Slattery
(Reuters) -China exempted some U.S. imports from its steep tariffs in a sign on Friday that the trade war between the two countries could be easing, though China quickly knocked down U.S. President Donald Trump's assertion that negotiations were underway.
Business groups said China has allowed some U.S.-made pharmaceuticals to enter the country without paying the 125% duties that Beijing imposed earlier this month in response to Trump's 145% tariffs on U.S. imports.
Also, a list of 131 product categories said to be under consideration for exemptions was circulating among some businesses and trade groups. Reuters could not verify the list, which includes vaccines, chemicals and jet engines, and China has not yet communicated publicly on the issue.
Trump's administration has in recent days signaled it is looking to de-escalate the confrontation between the world's two largest economies, and Trump himself told TIME magazine that talks were taking place and that Chinese President Xi Jinping had called him.
"I don't think it's a sign of weakness on his behalf," he said.
China denied that discussions were happening.
"China and the U.S. are NOT having any consultation or negotiation on #tariffs. The U.S. should stop creating confusion," the Chinese Embassy in Washington wrote on social media.
In addition to the steep tariffs on China, Trump has announced targeted tariffs on dozens of other countries, which he has suspended until July 9. That has set off a scramble among U.S. trading partners to strike individual trade deals with Washington before the deadline -- a tall order, given that past trade deals have typically taken years to negotiate.
Trump told reporters at the White House that he was very close to a deal with Japan. That is seen by analysts as a "test case" for other bilateral trade agreements, though talks could be difficult. Some expect Prime Minister Shigeru Ishiba and Trump to announce a pact when they meet at the G7 summit in Canada in June.
Trump separately told TIME that he had made "200 deals" that would be completed within three to four weeks, though he declined to provide specifics. He said he would consider it a "total victory" if tariffs were still 20% to 50% a year from now.
The office of the U.S. Trade Representative said it had held a productive meeting with South Korea on Friday.
Trump has argued that his thicket of trade barriers will revive U.S. manufacturing industries that have been hollowed out by global competition. Economists, however, broadly warn that they would lead to higher prices for U.S. consumers and increase the risk of recession.
In addition to the country-specific tariffs, Trump has also imposed a blanket 10% tariff on all other U.S. imports and higher duties on steel, aluminum and autos. He has also floated additional industry-specific levies on pharmaceuticals and semiconductors.
European and Asian stocks headed for a second straight week of gains on Friday and the dollar eyed its first weekly rise in more than a month, as investors took comfort from signs the U.S. and China were prepared to pull back from their trade war. Wall Street's main indexes opened slightly lower.
(Writing by Andy Sullivan; Editing by Chizu Nomiyama)

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Washington Post
9 minutes ago
- Washington Post
Fulbright board resigns over alleged Trump administration interference
The entire 12-person board tasked with overseeing the State Department's Fulbright Program resigned Wednesday, claiming political interference from the Trump administration. In a statement posted on the board's Substack, the congressionally mandated Fulbright Foreign Scholarship Board said its members voted 'overwhelmingly' to resign from the board 'rather than endorse unprecedented actions that we believe are impermissible under the law, compromise U.S. national interests and integrity, and undermine the mission and mandates Congress established for the Fulbright program nearly 80 years ago.'


New York Times
10 minutes ago
- New York Times
Pentagon Is Reviewing Deal to Equip Australia With Nuclear Submarines
The Trump administration is reviewing whether a security pact between the United States, Britain and Australia meant to equip Australia with nuclear submarines is 'aligned with the president's America First agenda,' a U.S. defense official said on Wednesday. When the deal was reached under President Joseph R. Biden Jr.'s administration in 2021, it was billed as crucial for countering China's growing military influence in the Asia Pacific. Now, its review appears to reinforce President Trump's skeptical and transactional approach to longstanding alliances, including demands that allies spend more on their own defense. The Pentagon official said the review would ensure that the pact, known as Aukus, met 'common-sense, America First criteria,' including ensuring that U.S. forces are at 'the highest readiness,' that allies are doing their part, and that 'the defense industrial base is meeting our needs.' The review was first reported by The Financial Times. Australia's defense minister, Richard Marles, said both Australia and Britain had been notified about the review and that all three nations were still committed to the deal. 'We've been aware of this for some time. We welcome it,' Mr. Marles said in a radio interview with ABC Melbourne on Thursday, Australia time. 'It's something which is perfectly natural for an incoming administration to do.' Australia sees the Aukus agreement as central to its defense strategy in the coming decades in a region increasingly shaped by China's assertive military posturing. Nuclear submarines can travel much farther without detection than conventional ones can and would enable the Australian Navy to greatly extend its reach. Under the pact, Australia is scheduled to receive secondhand Virginia-class nuclear submarines from the United States in the 2030s while scaling up the capacity to build its own, using a British design. But there has been concern in both Washington and Canberra about whether the United States can build new submarines to replenish its fleet quickly enough for the older ones to be transferred to Australia. Elbridge Colby, the U.S. under secretary of defense for policy, said during his Senate confirmation hearing in March that he was skeptical about the pragmatic feasibility of the deal. The Financial Times reported that Mr. Colby was heading up the Pentagon review. 'So if we can produce the attack submarines in sufficient number and sufficient speed, then great,' Mr. Colby said at the hearing. 'But if we can't, that becomes a very difficult problem.' Even before the review was announced, concern and anxiety had been building in Australia over whether it could continue to depend on its longstanding relationship with the United States, given the Trump administration's treatment of allies. Mr. Marles, the Australian defense minister, said in the radio interview that he was confident the Aukus deal would proceed because 'it's in the interests of the United States to continue to work with Australia.' Michael D. Shear contributed reporting from Washington.


Bloomberg
15 minutes ago
- Bloomberg
Bloomberg Daybreak Asia: Trump Says He'll Set Unilateral Tariffs; China's Biotech Boom
US equity-index futures dipped along with the dollar after President Donald Trump said he will set unilateral tariff rates within two weeks, dialing up trade tensions once again. The comments come a day after Chinese and US officials struck a positive tone following their talks to dial down trade tensions. Amid US talking with countries including India and Japan to lower the levies, some investors see Trump's comments as an effort to ramp up urgency in talks. We talk markets with Zachary Hill, Head of Portfolio Management at Horizon Investments. Plus - China's biotech industry is gaining momentum, with Pfizer and Bristol-Myers Squibb making billion-dollar deals with Chinese companies to license experimental cancer drugs. The industry is expected to continue growing, driven by factors such as US President Donald Trump's economic policies, cheaper and easier human testing in China, and an abundance of young and affordable engineering talent. We check in with Shuli Ren, Bloomberg Opinion Columnist, for a closer look at the sector.